Thomas A. Davis

6.6k total citations · 3 hit papers
47 papers, 5.2k citations indexed

About

Thomas A. Davis is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Thomas A. Davis has authored 47 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Immunology, 25 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Thomas A. Davis's work include Immunotherapy and Immune Responses (32 papers), Cancer Immunotherapy and Biomarkers (22 papers) and CAR-T cell therapy research (15 papers). Thomas A. Davis is often cited by papers focused on Immunotherapy and Immune Responses (32 papers), Cancer Immunotherapy and Biomarkers (22 papers) and CAR-T cell therapy research (15 papers). Thomas A. Davis collaborates with scholars based in United States, United Kingdom and India. Thomas A. Davis's co-authors include James P. Allison, Debra K. Czerwinski, David M. Harlan, John H. Fechner, Gary S. Gray, Xuening Hong, Stuart J. Knechtle, Nicholas Armstrong, Allan D. Kirk and Yinchen Dong and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Thomas A. Davis

46 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

2003 1.2k citations Giao Q. Phan, James Chih‐Hsin Yang et al. Proceedings of the National Academy of Sciences profile →
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

2003 778 citations Thomas A. Davis, James P. Allison et al. Proceedings of the National Academy of Sciences profile →
CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates

1997 776 citations David M. Harlan, Thomas A. Davis et al. Proceedings of the National Academy of Sciences profile →

Peers

Countries citing papers authored by Thomas A. Davis

Since Specialization

Citations

This map shows the geographic impact of Thomas A. Davis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas A. Davis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas A. Davis more than expected).

Fields of papers citing papers by Thomas A. Davis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas A. Davis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas A. Davis. The network helps show where Thomas A. Davis may publish in the future.

Co-authorship network of co-authors of Thomas A. Davis

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas A. Davis. A scholar is included among the top collaborators of Thomas A. Davis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas A. Davis. Thomas A. Davis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	485 Long term results from a phase 1 trial of GEN-009, a personalized neoantigen vaccine, combined with PD-1 inhibition in advanced solid tumors 2021 ·SHILAP Revista de lepidopterología ·Maura L. Gillison, Mark M. Awad, Przemyslaw Twardowski, Ammar Sukari, Melissa L. Johnson, Rudy P. Lackner, Mark N. Stein, Arthur P. DeCillis, Richard Hernandez, (unknown), (unknown), Mara G. Shainheit, (unknown), (unknown), (unknown), (unknown), Emily Tjon, Jessica B. Flechtner, Thomas A. Davis, Roger B. Cohen	1
2	An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers 2020 ·BMC Cancer ·Ewa Przybytkowski, Thomas A. Davis, Abdelrahman Hosny, Julia Eismann, Ursula A. Matulonis, Gerburg M. Wulf, Sheida Nabavi	23
3	In Situ Vaccination Improves Efficacy of PD-1 Blockade in Unresponsive Lymphoma Tumors through Induction of a Highly Efficient Cross-Presenting Dendritic Cell Subset Expressing TLR3 2017 ·Blood ·Linda Hammerich, Maxime Dhainaut, Tibor Keler, Thomas A. Davis, Andres Μ. Salazar, Brian D. Brown, Joshua Brody	1
4	Turning a Tumor into a Vaccine Factory: In Situ Vaccination for Low-Grade Lymphoma 2014 ·Blood ·Thomas U. Marron, Nina Bhardwaj, Elizabeth Crowley, Tibor Keler, Thomas A. Davis, Joshua Brody	3
5	Connecting Students to Content: Student-Generated Questions. 2013 ·Thomas A. Davis	5
6	Phase I Study Utilizing a Novel Antigen-Presenting Cell–Targeted Vaccine with Toll-like Receptor Stimulation to Induce Immunity to Self-antigens in Cancer Patients 2011 ·Clinical Cancer Research ·Michael A. Morse, Robert Chapman, John D. Powderly, Kimberly Blackwell, Tibor Keler, Jennifer Green, (unknown), (unknown), Venky Ramakrishna, Laura Vitale, Biwei Zhao, Stephen A. Butler, Amy Hobeika, Takuya Osada, Thomas A. Davis, Timothy Clay, H. Kim Lyerly	112
7	The Biology Major Capstone Experience: Measurements of Accountability. 2011 ·Thomas A. Davis	3
8	CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer 2011 ·Expert Review of Vaccines ·Michael A. Morse, Deborah Bradley, Tibor Keler, Robert J Laliberte, Jennifer A. Green, Thomas A. Davis, Brant A. Inman	39
9	Trauma is danger 2011 ·Journal of Translational Medicine ·(unknown), (unknown), Dylan Pannell, Thomas A. Davis, Eric A. Elster	21
10	Infusion of Lin− bone marrow cells results in multilineage macrochimerism and skin allograft tolerance in minimally conditioned recipient mice 2010 ·Transplant Immunology ·Khairul Anam, Mihret F. Amare, (unknown), Thomas A. Davis	3
11	Phase I clinical results of an APC-targeted hCGβ vaccine (CDX-1307) with TLR agonists 2009 ·Journal of Clinical Oncology ·Michael A. Morse, (unknown), John D. Powderly, Tibor Keler, Lihua He, Venky Ramakrishna, Laura Vitale, Timothy Clay, (unknown), Thomas A. Davis	2
12	Subcutaneous administration of genistein prior to lethal irradiation supports multilineage, hematopoietic progenitor cell recovery and survival 2007 ·International Journal of Radiation Biology ·Thomas A. Davis, (unknown), Steven Mog, Michael R. Landauer	71
13	Autoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody With Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV Melanoma 2004 ·Journal of Clinical Oncology ·Kristin M. Sanderson, (unknown), Peter P. Lee, Dongxin Liu, Susan Groshen, Jolie Snively, Shirley Sian, Geoffrey Nichol, Thomas A. Davis, Tibor Keler, Michael Yellin, Jeffrey S. Weber	322
14	Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma breakdown → 2003 ·Proceedings of the National Academy of Sciences ·Giao Q. Phan, James Chih‐Hsin Yang, Richard M. Sherry, Patrick Hwu, Suzanne L. Topalian, Douglas J. Schwartzentruber, Nicholas P. Restifo, Leah Haworth, Claudia A. Seipp, (unknown), Kathleen E. Morton, Sharon Mavroukakis, Paul H. Duray, Seth M. Steinberg, James P. Allison, Thomas A. Davis, Steven A. Rosenberg	1234
15	Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma 2001 ·Biology of Blood and Marrow Transplantation ·Thomas A. Davis, Frank J. Hsu, Clemens B. Caspar, (unknown), Debra K. Czerwinski, (unknown), Behnaz Taidi, Claudia Benike, Edgar G. Engleman, Ronald Levy	27
16	Susceptibility or resistance toLeishmania infection is dictated by the macrophages evolved under the influence of IL-3 or GM-CSF 1999 ·European Journal of Immunology ·Bhaskar Saha, (unknown), (unknown), P J Perrin, David M. Harlan, Thomas A. Davis	36
17	Phorbol Esters Induce Differentiation of Human CD34+ Hemopoietic Progenitors to Dendritic Cells: Evidence for Protein Kinase C-Mediated Signaling 1998 ·The Journal of Immunology ·Thomas A. Davis, (unknown), Patrick J. Blair, Bruce L. Levine, Nancy Craighead, David M. Harlan, Carl H. June, Kelvin P. Lee	66
18	Mitogenic stimulation of T cells reveals differing contributions for B7‐1 (CD80) and B7‐2 (CD86) costimulation 1997 ·Immunology ·P J Perrin, Thomas A. Davis, Douglas S. Smoot, Ryo Abe, Carl H. June, (unknown)	43
19	Primary porcine endothelial cells express membrane-bound B7-2 (CD86) and a soluble factor that co-stimulate cyclosporin A-resistant and CD28-dependent human T cell proliferation 1996 ·International Immunology ·Thomas A. Davis, Nancy Craighead, Amanda Williams, (unknown), Carl H. June, Kelvin P. Lee	44
20	CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis 1996 ·The Journal of Immunology ·P J Perrin, (unknown), Thomas A. Davis, Carl H. June, Michael K. Racke	206

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact